Audentes Therapeutics launched a new South San Francisco-based internal cGMP plasmid manufacturing facility which, the company says, is expected to significantly enhance a critical element of its supply chain, i.e., provide high-quality nonclinical and cGMP-grade plasmids for all of its development programs. Andentes is an AAV-based genetic medicines company focused on developing and commercializing products for […]
The post Audentes Launches Internal cGMP Plasmid Manufacturing Facility appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Audentes Launches Internal cGMP Plasmid Manufacturing Facility